Protara Therapeutics, Inc. (TARA)
3.78
-0.19
(-4.79%)
USD |
NASDAQ |
Jun 10, 16:00
3.89
+0.11
(+2.91%)
Pre-Market: 09:19
Protara Therapeutics SG&A Expense (Quarterly) : 6.067M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 6.067M |
| December 31, 2025 | 5.955M |
| September 30, 2025 | 5.169M |
| June 30, 2025 | 5.816M |
| March 31, 2025 | 4.976M |
| December 31, 2024 | 4.813M |
| September 30, 2024 | 4.26M |
| June 30, 2024 | 4.274M |
| March 31, 2024 | 4.103M |
| December 31, 2023 | 4.66M |
| September 30, 2023 | 4.482M |
| June 30, 2023 | 4.893M |
| March 31, 2023 | 4.589M |
| December 31, 2022 | 5.003M |
| September 30, 2022 | 4.508M |
| June 30, 2022 | 5.621M |
| March 31, 2022 | 5.605M |
| December 31, 2021 | 6.219M |
| September 30, 2021 | 6.737M |
| June 30, 2021 | 6.905M |
| March 31, 2021 | 6.54M |
| December 31, 2020 | 5.305M |
| September 30, 2020 | 2.796M |
| June 30, 2020 | 4.796M |
| March 31, 2020 | 7.095M |
| Date | Value |
|---|---|
| December 31, 2019 | 1.804M |
| September 30, 2019 | 1.256M |
| June 30, 2019 | 0.442M |
| March 31, 2019 | 0.4502M |
| December 31, 2018 | 2.722M |
| September 30, 2018 | 2.268M |
| June 30, 2018 | 2.24M |
| March 31, 2018 | 2.294M |
| December 31, 2017 | 2.377M |
| September 30, 2017 | 1.97M |
| June 30, 2017 | 2.095M |
| March 31, 2017 | 2.234M |
| December 31, 2016 | 2.429M |
| September 30, 2016 | 2.324M |
| June 30, 2016 | 2.613M |
| March 31, 2016 | 2.47M |
| December 31, 2015 | 2.607M |
| September 30, 2015 | 2.004M |
| June 30, 2015 | 1.891M |
| March 31, 2015 | 1.987M |
| December 31, 2014 | 1.399M |
| September 30, 2014 | 1.041M |
| June 30, 2014 | 0.912M |
| March 31, 2014 | 0.744M |
| September 30, 2013 | 0.943M |
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| NovelStem International Corp. | 0.005M |
| Brainstorm Cell Therapeutics, Inc. | 1.284M |
| Summit Therapeutics, Inc. | 62.59M |
| Kezar Life Sciences, Inc. | 5.208M |
| Clene, Inc. | 1.747M |